Back to News
Market Impact: 0.3
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesPatents & Intellectual Property
Ascendis will regain all rights to TransCon technology-based metabolic and cardiovascular products, including once-monthly TransCon Semaglutide. The company plans to initiate multiple development programs spanning obesity, metabolic disease and cardiovascular indications, expanding control of its pipeline in high-growth therapeutic markets.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ASND0.72
More News
- Google's Gemini 4 Carbon looks like a diamond in the rough
- Fed chairman talks tough on inflation — plus, what's behind Micron's big rally
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- Investors Eye AI Payoff in Microsoft, Alphabet Earnings
- Apple brings touch to the Mac, reversing years-old stance on touchscreen laptop
- The 2,000-Nit OLED in Apple’s New MacBook Is a Big Deal